ATXS Phase 2 readout: a partial negative outcome, -7.0%

On March 13, 2025, STAR-0215 — Astria Therapeutics, Inc. (Hereditary Angioedema) reached its Phase 2 readout. The result was a partial negative outcome, and the stock moved -7.0% in the window around the event. It had already run -14.9% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.